|
Disease characteristics
|
|
SMM
|
7%
|
(4)
|
9%
|
(2)
|
5%
|
(1)
|
7%
|
(1)
|
|
SMM/MM subtype
|
|
IgD
|
2%
|
(1)
|
5%
|
(1)
|
0%
|
(0)
|
0%
|
(0)
|
|
IgG
|
59%
|
(34)
|
59%
|
(13)
|
64%
|
(14)
|
50%
|
(7)
|
|
IgA
|
19%
|
(11)
|
23%
|
(5)
|
14%
|
(3)
|
21%
|
(3)
|
|
Light chain disease
|
33%
|
(19)
|
23%
|
(5)
|
41%
|
(9)
|
36%
|
(5)
|
|
Extramedullary disease history
|
31%
|
(18)
|
36%
|
(8)
|
32%
|
(7)
|
21%
|
(3)
|
|
ISS at diagnosis
|
|
1
|
33%
|
(18/54)
|
45%
|
(9/20)
|
43%
|
(9/21)
|
0%
|
(0/13)
|
|
2
|
26%
|
(14/54)
|
25%
|
(5/20)
|
33%
|
(7/21)
|
15%
|
(2/13)
|
|
3
|
19%
|
(10/54)
|
20%
|
(4/20)
|
14%
|
(3/21)
|
23%
|
(3/13)
|
|
Not known
|
22%
|
(12/54)
|
10%
|
(2/20)
|
10%
|
(2/21)
|
62%
|
(8/13)
|
|
High-risk cytogenetics
|
39%
|
(22/56)
|
33%
|
(7/21)
|
41%
|
(9)
|
46%
|
(6/13)
|
|
Time since MM diagnosis (months)
|
29.8
|
[44.2]
|
44.8
|
[38.7]
|
27.2
|
[55.8]
|
28.6
|
[23.6]
|
|
History of ASCT
|
41%
|
(22/54)
|
60%
|
(12/20)
|
24%
|
(5/21)
|
38%
|
(5/13)
|
|
Time since ASCT (days)
|
985
|
[1590]
|
985
|
[744]
|
2148
|
[2206]
|
460
|
[1734]
|
|
ASCT within last year
|
9%
|
(5/54)
|
15%
|
(3/20)
|
0%
|
(0/21)
|
15%
|
(2/13)
|
|
Lines of therapy (n)
|
1.5
|
[2]
|
2
|
[2]
|
2
|
[3]
|
1
|
[1]
|
|
More than 4 lines of treatment
|
17%
|
(9/54)
|
20%
|
(4/20)
|
19%
|
(4/21)
|
8%
|
(1/13)
|
|
ECOG 0
|
47%
|
(27)
|
64%
|
(14)
|
41%
|
(9)
|
29%
|
(4)
|
|
Current response status*
|
|
sCR or CR
|
26%
|
(15)
|
45%
|
(10)
|
14%
|
(3)
|
14%
|
(2)
|
|
VGPR
|
19%
|
(11)
|
18%
|
(4)
|
14%
|
(3)
|
29%
|
(4)
|
|
PR
|
22%
|
(13)
|
18%
|
(4)
|
23%
|
(5)
|
29%
|
(4)
|
|
SD
|
3%
|
(2)
|
5%
|
(1)
|
5%
|
(1)
|
0%
|
(0)
|
|
PD
|
16%
|
(9)
|
5%
|
(1)
|
23%
|
(5)
|
21%
|
(3)
|
|
Not evaluable
|
14%
|
(8)
|
9%
|
(2)
|
23%
|
(5)
|
7%
|
(1)
|
|
Current MM treatment regimen
|
|
Contains CD38 mAb
|
48%
|
(28)
|
50%
|
(11)
|
50%
|
(11)
|
43%
|
(6)
|
|
Contains IMiD
|
55%
|
(32)
|
55%
|
(12)
|
59%
|
(13)
|
50%
|
(7)
|
|
Contains proteasome inhibitor
|
38%
|
(22)
|
27%
|
(6)
|
41%
|
(9)
|
50%
|
(7)
|
|
Contains corticosteroids
|
52%
|
(30)
|
45%
|
(10)
|
50%
|
(11)
|
64%
|
(9)
|
|
Contains venetoclax
|
9%
|
(5)
|
14%
|
(3)
|
9%
|
(2)
|
0%
|
(0)
|
|
No active treatment
|
19%
|
(11)
|
18%
|
(4)
|
18%
|
(4)
|
21%
|
(3)
|
|
Biochemical parameters at last clinic visit before COVID-19 episode
|
|
Leukocyte count (× 10e9/L)
|
4.6
|
[2.1]
|
4.1
|
[2.1]
|
5.2
|
[2.4]
|
4.7
|
[1.5]
|
|
Leukocytopenia (< 4 × 10e9/L)
|
35%
|
(20/57)
|
41%
|
(9)
|
33%
|
(7/21)
|
29%
|
(4)
|
|
Absolute neutrophil count (× 10e9/L)
|
2.6
|
[2.2]
|
2.4
|
[1]
|
3.4
|
[3]
|
2.4
|
[1.4]
|
|
Neutropenia (< 2 × 10e9/L)
|
26%
|
(15/57)
|
32%
|
(7)
|
29%
|
(6/21)
|
14%
|
(2)
|
|
Absolute lymphocyte count (× 10e9/L)
|
1
|
[0.8]
|
1.1
|
[1.2]
|
0.8
|
[0.9]
|
1.2
|
[0.5]
|
|
Lymphocytopenia (< 0.5 × 10e9/L)
|
12%
|
(7/57)
|
0%
|
(0)
|
33%
|
(7/21)
|
0%
|
(0)
|
|
Serum free light chain ratio (involved/uninvolved)
|
2.5
|
[11.9]
|
1.6
|
[3.3]
|
7.7
|
[45.5]
|
1.8
|
[5.2]
|
|
M spike (g/dL)
|
0
|
[0.6]
|
0
|
[0.2]
|
0.3
|
[1.2]
|
0.1
|
[0.4]
|
|
IgG (mg/dL)
|
805
|
[736]
|
1074.5
|
[683.8]
|
764
|
[1121]
|
727
|
[496.8]
|
|
Hypogammaglobulinemia (IgG < 700 mg/dL)
|
37%
|
(21/57)
|
32%
|
(7)
|
38%
|
(8/21)
|
43%
|
(6)
|
|
Severe hypogammaglobulinemia (IgG < 400 mg/dL)
|
11%
|
(6/57)
|
0%
|
(0)
|
10%
|
(2/21)
|
29%
|
(4)
|
|
Immunoparesis
|
89%
|
(51/57)
|
82%
|
(18)
|
95%
|
(20/21)
|
93%
|
(13)
|
